2.415USD-2.23%Mkt Cap: 451.67M USDP/E: —Last update: 2026-05-26
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The co…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap451.67M USD
Enterprise Value312.95M USD
Revenue (TTM)7.12M USD
Gross Profit7.12M USD
Net Income (TTM)-17.41M USD
Revenue/Share0.0790 USD
Last Price2.415 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6904691010
Valuation
P/E (Trailing)—
P/E (Forward)-5.42
PEG—
EV/EBITDA-6.58
EV/Revenue43.94
P/S63.94
P/B2.43
EPS (TTM)-0.21
EPS (Forward)-0.45
52W Range
0.270076% of range3.105
52W High3.105 USD
52W Low0.2700 USD
Profitability
Gross Margin100.00%
Oper. Margin-670.25%
EBITDA Margin0.00%
Profit Margin-240.13%
ROE-13.33%
ROA-11.54%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-38.33M USD
CapEx (TTM)—
FCF Margin-283.86%
FCF Yield-4.48%
Net Debt-142.45M USD
Net Debt/EBITDA2.99
Balance Sheet
Debt/Equity0.10
Current Ratio10.17
Quick Ratio9.88
Book Value/Sh1.004 USD
Cash/Share0.8330 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)5.471 USD
Target Range4.000 USD – 7.000 USD
# Analysts9
Ownership
Shares Out.186.64M
Float161.29M
Insiders6.98%
Institutions56.43%
Short Interest
Short Ratio2.9d
Short % Float5.75%
Short % Out.4.93%
Shares Short8.53M
Short (prev mo.)9.34M
Technical
SMA 502.564 (-5.8%)
SMA 2001.738 (+38.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.05M
Avg Vol (10d)1.91M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—